Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.47 +0.88 (+1.93%)
Official Closing Price Updated: 4:10 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
82 83 Next >
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative. 
Via Chartmill
Topics Government World Trade
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries. 
Via Stocktwits
Topics Government
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression. 
Via Benzinga
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
BMY Q1 Earnings Call: Growth Portfolio Offsets Declines, Guidance Raised Amid Pipeline Advancements
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 5.6% year on year to $11.2 billion. The company’s... 
Via StockStory
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) stands out as a stock that provides good value for the fundamentals it showcases.
BRISTOL-MYERS SQUIBB CO has a stellar value proposition. NYSE:BMY not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
3 Healthcare Stocks in Hot Water
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Economy Stocks
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings
 
Via Benzinga
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers. 
Via Chartmill
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
From Bristol Myers Squibb
Via Business Wire
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review. 
Via Benzinga
1 Stock Under $50 with Solid Fundamentals and 2 to Keep Off Your Radar
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock Worth Considering
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock Worth Considering 
Via Chartmill
This High-Yield Pharma Stock Looks Like an Incredible Bargain
Via The Motley Fool
Topics Intellectual Property
Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet
Recent upticks in the market may disguise the ongoing risks that remain for investors; these factors point to the importance of a defensive strategy. 
Via MarketBeat
Topics Economy Government World Trade
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
Top 3 Health Care Stocks That May Rocket Higher In April
 
Via Benzinga
Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Government World Trade
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Economy Intellectual Property World Trade
S&P 500 Rallies 2% On Nvidia, Tesla Gains — But Market Mood Stuck In 'Fear'
 
Via Benzinga
Topics Stocks
Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results
 
Via Benzinga
Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact
Bristol Myers reported Q1 revenue of $11.2 billion, raised 2025 guidance, and saw strong Growth Portfolio sales offset Legacy product declines. 
Via Benzinga
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
Bristol Myers Reports Upbeat Q1 Earnings, Raises Full-Year Guidance: Retail’s Optimistic
The company now expects full-year diluted EPS in the range of $6.70 to $7.00, up from its previous guidance of $6.55 to $6.85. 
Via Stocktwits
Topics World Trade
Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates
The company recently faced two big clinical trial setbacks that have weighed on shares recently. 
Via Investor's Business Daily
Topics Government
Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 5.6% year on year to $11.2 billion. The company’s... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.